IO Biotech (IOBT) Expected to Announce Earnings on Tuesday

Key Points

• IO Biotech is set to announce its Q2 2025 earnings results on August 12th, with analysts predicting a loss of ($0.35) per share.
• The company's stock recently traded at $2.11, with a trading volume of 39,725 shares, significantly less than its average volume of 217,228.
• Wall Street analysts have issued mixed ratings on IO Biotech, with one upgrade to a "sell" rating and another maintaining a "buy" rating.

IO Biotech (NASDAQ:IOBT - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect IO Biotech to post earnings of ($0.35) per share for the quarter.

IO Biotech Trading Down 8.8%

IOBT opened at $1.96 on Thursday. The firm has a market cap of $141.64 million, a price-to-earnings ratio of -1.32 and a beta of 0.44. The stock has a fifty day moving average price of $1.65 and a 200-day moving average price of $1.20. IO Biotech has a 12 month low of $0.66 and a 12 month high of $2.48.

Institutional Investors Weigh In On IO Biotech

A hedge fund recently bought a new stake in IO Biotech stock. Jane Street Group LLC acquired a new stake in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 23,717 shares of the company's stock, valued at approximately $26,000. 54.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on IOBT shares. HC Wainwright reiterated a "buy" rating on shares of IO Biotech in a research report on Wednesday, May 14th. Wall Street Zen raised IO Biotech to a "sell" rating in a report on Saturday, June 14th.

About IO Biotech

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.